A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with anthracyclines and taxanes. This study aimed to evaluate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	irinotecan metastatic breast cancer efficacy chemotherapy palliative therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ff823bd8ac78446d8430437deb181d7f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff823bd8ac78446d8430437deb181d7f
record_format	dspace
spelling	oai:doaj.org-article:ff823bd8ac78446d8430437deb181d7f2021-11-22T05:08:15ZA Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes2234-943X10.3389/fonc.2021.654974https://doaj.org/article/ff823bd8ac78446d8430437deb181d7f2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.654974/fullhttps://doaj.org/toc/2234-943XBackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with anthracyclines and taxanes. This study aimed to evaluate the efficacy of irinotecan-based chemotherapy for breast cancer patients in a metastatic setting.MethodsWe retrospectively collected the clinical information and survival data of 51 patients with MBC who received irinotecan at West China Hospital of Sichuan University. The primary endpoints were the progression free survival (PFS) and overall survival (OS), and the secondary endpoint was the objective response rate (ORR). To minimize potential confounding factors, we matched 51 patients who received third-line chemotherapy without irinotecan through propensity score matching (PSM) based on age, hormone receptor (HR), and human epidermal growth factor receptor 2 (HER2), compared their OS and PFS rates to those treated with irinotecan.ResultsFrom July 2012 to October 2020, 51 patients were treated with an irinotecan-containing regimen. The median number of previous treatment lines was 4, and a median of two previous chemotherapy cycles (ranging from 1–14 cycles) were given in a salvage line setting. The ORR was 15.7%, and the disease control rate (DCR) was 37.3%. For the irinotecan group, the median PFS was 3.2 months (95% CI 2.7–3.7), while the median OS was 33.1 months (95% CI 27.9–38.3). Univariate analysis results suggested that irinotecan could improve PFS in patients with visceral metastasis (P=0.031), which was 0.7 months longer than patients without visceral metastasis (3.5 months vs. 2.8 months). Compared to the patients who received third-line non-irinotecan chemotherapy, the irinotecan group showed a longer trend of PFS without statistical significance (3.2 months vs 2.1 months, P = 0.052). Similarly, the OS of the irinotecan group was longer than the third-line survival without irinotecan, but it was not statistically significant (33.1 months vs 18.0 months, P = 0.072).ConclusionsFor MBC patients who were previously treated with anthracyclines and/or taxanes, an irinotecan-containing regimen achieved moderate objective response and showed a trend of survival benefit, which deserves further study.Jiaojiao SuoXiaorong ZhongXiaorong ZhongPing HePing HeHong ZhengHong ZhengTinglun TianTinglun TianXi YanXi YanTing LuoTing LuoFrontiers Media S.A.articleirinotecanmetastatic breast cancerefficacychemotherapypalliative therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	irinotecan metastatic breast cancer efficacy chemotherapy palliative therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	irinotecan metastatic breast cancer efficacy chemotherapy palliative therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jiaojiao Suo Xiaorong Zhong Xiaorong Zhong Ping He Ping He Hong Zheng Hong Zheng Tinglun Tian Tinglun Tian Xi Yan Xi Yan Ting Luo Ting Luo A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
description	BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with anthracyclines and taxanes. This study aimed to evaluate the efficacy of irinotecan-based chemotherapy for breast cancer patients in a metastatic setting.MethodsWe retrospectively collected the clinical information and survival data of 51 patients with MBC who received irinotecan at West China Hospital of Sichuan University. The primary endpoints were the progression free survival (PFS) and overall survival (OS), and the secondary endpoint was the objective response rate (ORR). To minimize potential confounding factors, we matched 51 patients who received third-line chemotherapy without irinotecan through propensity score matching (PSM) based on age, hormone receptor (HR), and human epidermal growth factor receptor 2 (HER2), compared their OS and PFS rates to those treated with irinotecan.ResultsFrom July 2012 to October 2020, 51 patients were treated with an irinotecan-containing regimen. The median number of previous treatment lines was 4, and a median of two previous chemotherapy cycles (ranging from 1–14 cycles) were given in a salvage line setting. The ORR was 15.7%, and the disease control rate (DCR) was 37.3%. For the irinotecan group, the median PFS was 3.2 months (95% CI 2.7–3.7), while the median OS was 33.1 months (95% CI 27.9–38.3). Univariate analysis results suggested that irinotecan could improve PFS in patients with visceral metastasis (P=0.031), which was 0.7 months longer than patients without visceral metastasis (3.5 months vs. 2.8 months). Compared to the patients who received third-line non-irinotecan chemotherapy, the irinotecan group showed a longer trend of PFS without statistical significance (3.2 months vs 2.1 months, P = 0.052). Similarly, the OS of the irinotecan group was longer than the third-line survival without irinotecan, but it was not statistically significant (33.1 months vs 18.0 months, P = 0.072).ConclusionsFor MBC patients who were previously treated with anthracyclines and/or taxanes, an irinotecan-containing regimen achieved moderate objective response and showed a trend of survival benefit, which deserves further study.
format	article
author	Jiaojiao Suo Xiaorong Zhong Xiaorong Zhong Ping He Ping He Hong Zheng Hong Zheng Tinglun Tian Tinglun Tian Xi Yan Xi Yan Ting Luo Ting Luo
author_facet	Jiaojiao Suo Xiaorong Zhong Xiaorong Zhong Ping He Ping He Hong Zheng Hong Zheng Tinglun Tian Tinglun Tian Xi Yan Xi Yan Ting Luo Ting Luo
author_sort	Jiaojiao Suo
title	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
title_short	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
title_full	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
title_fullStr	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
title_full_unstemmed	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
title_sort	retrospective analysis of the effect of irinotecan-based regimens in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/ff823bd8ac78446d8430437deb181d7f
work_keys_str_mv	AT jiaojiaosuo aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiaorongzhong aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiaorongzhong aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT pinghe aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT pinghe aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT hongzheng aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT hongzheng aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluntian aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluntian aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiyan aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiyan aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluo aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluo aretrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT jiaojiaosuo retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiaorongzhong retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiaorongzhong retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT pinghe retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT pinghe retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT hongzheng retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT hongzheng retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluntian retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluntian retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiyan retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT xiyan retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluo retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes AT tingluo retrospectiveanalysisoftheeffectofirinotecanbasedregimensinpatientswithmetastaticbreastcancerpreviouslytreatedwithanthracyclinesandtaxanes
_version_	1718418200812584960

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Ejemplares similares